

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* 5AM Ventures IV, L.P. (Last) (First) (Middle) 501 2ND STREET, SUITE 350 (Street) SAN FRANCISCO CA 94107 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Homology Medicines, Inc. [FIXX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 04/02/2018	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/02/2018		C		5,392,037	A	\$0	6,722,076	I	See footnotes ⁽¹⁾⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(3)	04/02/2018		C		4,204,502		(3)	(3)	Common Stock	4,204,502	\$0	0	I	See footnote ⁽²⁾
Series B Preferred Stock	(3)	04/02/2018		C		1,187,535		(3)	(3)	Common Stock	1,187,535	\$0	0	I	See footnote ⁽²⁾

1. Name and Address of Reporting Person*
5AM Ventures IV, L.P.
 (Last) (First) (Middle)
501 2ND STREET, SUITE 350
 (Street)
SAN FRANCISCO CA 94107
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
5AM Partners IV, LLC
 (Last) (First) (Middle)
501 2ND STREET, SUITE 350
 (Street)
SAN FRANCISCO CA 94107
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
ROCKLAGE SCOTT M
 (Last) (First) (Middle)
501 2ND STREET, SUITE 350
 (Street)

SAN FRANCISCO	CA	94107
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
DIEKMAN JOHN D		
(Last)	(First)	(Middle)
501 2ND STREET, SUITE 350		
(Street)		
SAN FRANCISCO	CA	94107
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Schwab Andrew J.		
(Last)	(First)	(Middle)
501 2ND STREET, SUITE 350		
(Street)		
SAN FRANCISCO	CA	94107
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
5AM Co-Investors IV, L.P.		
(Last)	(First)	(Middle)
501 2ND STREET, SUITE 350		
(Street)		
SAN FRANCISCO	CA	94107
(City)	(State)	(Zip)

Explanation of Responses:

- Following the transactions reported herein, includes 6,453,195 shares of Common Stock held of record by 5AM Ventures IV, L.P. ("Ventures IV") and 268,881 shares of Common Stock held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV").
- 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.
- Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock was automatically converted into one share of the Issuer's common stock.

5AM VENTURES IV, L.P. By:	
5AM Partners IV, LLC, its	
General Partner /s/ Scott M.	04/04/2018
Rocklage Managing Member	
5AM CO-INVESTORS IV, L.P.	
By: 5AM Partners IV, LLC, its	
General Partner /s/ Scott M.	04/04/2018
Rocklage Managing Member	
5AM PARTNERS IV, LLC /s/	
Scott M. Rocklage Managing	04/04/2018
Member	
/s/ Scott M. Rocklage	04/04/2018
/s/ John D. Diekman	04/04/2018
/s/ Andrew J. Schwab	04/04/2018
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.